Roots Analysis Identifies Top 10 Peptide Synthesis Companies
Market research firm Roots Analysis has identified the top 10 companies involved in peptide synthesis contract manufacturing for 2024. The list is based on companies' service portfolios and market presence.
Market research firm Roots Analysis has published a report identifying the top 10 companies engaged in peptide synthesis contract manufacturing for 2024. The report analyzed over 75 companies focusing on the contract manufacturing of peptide active pharmaceutical ingredients (APIs).
Peptides are critical signaling molecules that regulate physiological and metabolic functions within the body. The field of peptide-based therapeutics has seen significant growth in recent years, with over 80 peptide drugs approved globally and more than 300 currently in clinical trials.
The increasing demand for peptide drugs, particularly GLP-1 medications, coupled with technological advancements, is expected to drive long-term growth in the peptide synthesis market. The report provided an in-depth analysis of the market landscape and future opportunities for contract manufacturing service providers in this sector over a 12-year span.
The 10 leading companies identified, listed alphabetically, are: AmbioPharm, Auspep, Bachem, BCN Peptides, Chinese Peptide, CordenPharma, CPC Scientific, CSBio, Peptide Institute, and PolyPeptide. The report offers a deeper look into the operations and services of five of these companies: AmbioPharm, Auspep, Bachem, BCN Peptides, and Chinese Peptide.